QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=FE390919606FA9CDF00B0C61A4202833;jsessionid=3F5DFB266FBDD5A19ACBEA654DC8EC54;jsessionid=CF323899DE1C3F386C07DC837372A6D7;jsessionid=FC512DD6FCDB1B5EF8FBCB93ECB77BFF;jsessionid=F11ECE75C16142B0F5856C1FE311673A;jsessionid=6232C3735BF985A4029696E93EF01E40;jsessionid=40E9FE0F41F0AD03D413B31CDF75ADBF (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=F814328285108F7A4EA0DA28CFE696D7;jsessionid=502E776C630F24248151AAEED05D5B46;jsessionid=FE390919606FA9CDF00B0C61A4202833;jsessionid=3F5DFB266FBDD5A19ACBEA654DC8EC54;jsessionid=CF323899DE1C3F386C07DC837372A6D7;jsessionid=FC512DD6FCDB1B5EF8FBCB93ECB77BFF;jsessionid=F11ECE75C16142B0F5856C1FE311673A;jsessionid=6232C3735BF985A4029696E93EF01E40;jsessionid=40E9FE0F41F0AD03D413B31CDF75ADBF